Tempus AI Swings to Profit, Raises Guidance to $1.6 Billion, and Buys Its Way Into Cancer Blood Tests
Tempus AI posted a $5.64 million net profit in Q2 2026 after a $42.84 million loss a year earlier, raised full-year guidance, and moved to acquire Personalis to expand into tumor-monitoring blood tests.